A ginkgo extract used to treat Alzheimer’s has been found to be effective in preventing dementia and Alzheimer’s-related cognitive decline in a double-blind study of more than 6,000 people.
Researchers at the University of Oxford looked at the use of the herbal extract, which is used to relieve the symptoms of Alzheimer’s, Parkinson’s and multiple sclerosis.
The results, published online Wednesday, found the herb was associated with a reduction in the risk of dementia and cognitive decline compared to placebo.
Ginkgo has been used as a treatment for years to treat a variety of ailments, including rheumatoid arthritis, heart disease, diabetes and hypertension.
In recent years, it has become a popular ingredient in other health products, including probiotics, cough drops and painkillers.
But the drug industry is wary of the drug’s potential side effects.
The Oxford study looked at data from more than 1,300 participants, ages 65 and older, who took a combination of ginkgosin and methylene blue for five years.
The researchers looked at people who had developed dementia, and compared the participants who took the ginkgone extract to those who did not.
They found that those who took ginkgasin showed significantly lower rates of dementia compared to those taking the placebo.
The researchers also looked at dementia rates in people taking ginkgsolimine, a drug that helps treat Parkinson’s disease.
They didn’t find a significant difference in rates.
The authors of the study, led by Dr. David S. Tapp, also say the results should be taken with a grain of salt because there were only six participants in the study and the results weren’t necessarily representative of the U.S. population.
“The results, although interesting, are not necessarily representative for the U,S.
as a whole,” said Dr. Daniel W. Brown, an associate professor of medicine and neuroscience at the Harvard Medical School and an author of the paper.
“This is an important, small study and so we’re very cautious about interpreting them.”
Brown said the study is preliminary and needs more data to confirm the findings.
The study’s authors, led with Dr. S. David L. Brown of Harvard Medical Schools Medical Center and Dr. John F. Teller of the University at Albany, did not respond to requests for comment.
The U.K.-based British Association of Alzheimer Disease also didn’t respond to a request for comment, but said in a statement:”There is no conclusive evidence to support the use or safety of the Ginkgogo compound as an Alzheimer’s treatment.
The association welcomes further research into this important area.”
Follow LiveScience for the latest in science news and discoveries on Twitter @livescience.